Medication Guide App

Generic DDAVP Availability

DDAVP is a brand name of desmopressin, approved by the FDA in the following formulation(s):

DDAVP (desmopressin acetate - injectable;injection)

DDAVP (desmopressin acetate - solution;nasal)

DDAVP (desmopressin acetate - tablet;oral)

Has a generic version of DDAVP been approved?

A generic version of DDAVP has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to DDAVP and have been approved by the FDA:

desmopressin acetate injectable;injection

  • Manufacturer: HOSPIRA
    Approval date: August 28, 2000
    Strength(s): 0.004MG/ML [AP]
  • Manufacturer: SUN PHARM INDS LTD
    Approval date: January 25, 2013
    Strength(s): 0.004MG/ML [AP]
  • Manufacturer: TEVA PHARMS USA
    Approval date: October 15, 1997
    Strength(s): 0.004MG/ML [AP]

desmopressin acetate solution;nasal

  • Manufacturer: SUN PHARM INDS
    Approval date: April 12, 2012
    Strength(s): 0.01% [AB]

desmopressin acetate tablet;oral

  • Manufacturer: APOTEX INC
    Approval date: March 7, 2006
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: January 25, 2006
    Strength(s): 0.1MG [AB], 0.2MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: July 1, 2005
    Strength(s): 0.1MG [AB], 0.2MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DDAVP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • High purity desmopressin produced in large single batches
    Patent 5,674,850
    Issued: October 7, 1997
    Inventor(s): Larsson; Krister & Mellbrand; Thomas & Mornstam; Birgitta & Roschester; Jan & Skoldback; Jan-Ake
    Assignee(s): Ferring AB
    A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating diabetes insipidus with the high purity desmopressin produced therefrom.
    Patent expiration dates:
    • December 23, 2013
  • Pharmaceutical composition as solid dosage form and method for manufacturing thereof
    Patent 7,022,340
    Issued: April 4, 2006
    Inventor(s): Lomryd; Hakan & Nicklasson; Helena & Olsson; Lars-Erik
    Assignee(s): Ferring B.V.
    The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof; wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.
    Patent expiration dates:
    • April 30, 2023
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide
(web3)